Vistagen Reports Positive Results from P-IIa Study of PH15 for Improvement of Psychomotor Impairment
Shots: Vistagen reports P-IIa study (n=10) results, PH15 (1.6µg) shown stati...
Atom Bioscience Initiates Enrolment in Global P-IIb/III Study of ABP-671 to Treat Chronic Gout in US
Shots: Atom Bioscience initiated patient enrolment in the US for a
CureVac collaborates with GSK to Initiate P-I/II study of Avian Influenza (H5N1)
Shots: CureVac announced initiation of P-I part of P-I/II study to evaluate influe...
Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD
Shots: Neurocrine reports results from SAVITRI, a P-II study (n=183), evaluating s...
Sanofi’s Rilzabrutinib Meets Primary Endpoint of the LUNA-3 (P-III) Study for the Treatment of Immune Thrombocytopenia (ITP)
Shots: The P-III trial (LUNA 3) evaluated the safety & efficacy of rilzabrutin...
Krystal Biotech doses First Patient with Inhaled KB707 in the P-I study for treating Locally Advanced or Metastatic Solid Tumors o...
Shots: Krystal has begun first patient dosing of KYANITE-1 (
